Selexis SA and NKT Therapeutics (NKTT) have entered into a research services agreement under which Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their INTEGRA-D2M platform. The platform enables the rapid isolation of production cell lines associated with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. The selected CHO-based protein variant expressing clone can then be us...